Lupin Boss On Getting Biosimilar Manufacturing Right, Albuterol Outlook

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.

Nilesh Gupta
Lupin's managing director Nilesh Gupta

Lupin Ltd. isn’t fretting about not being among the early movers in the biosimilars space and believes that those who can get the manufacturing of these products right could potentially hold a distinct edge.

In an interview with Scrip, the Indian company’s managing director Nilesh Gupta reiterated that being early in the biosimilars sector...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip